|Day Low/High||68.01 / 69.15|
|52 Wk Low/High||49.24 / 70.18|
Knowing when to continue to fish or cut bait is something that develops over time in this space.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
I would add to them on any significant dips in the market.
One of pharma's biggest CEO's talks M&A action on the exchange.
European stocks slip as Apple earnings take the steam out of the global equity rally.
Why the name is sagging, and what it will take to spur the sector higher.
Demographic trends that boosted big gains in prior years haven't gone away.
Here are stocks with solid fundamentals at some of the best absolute entry points in years.
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Today there was a virtual vacuum of good news in the stock market.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
In a "take no pain, take no prisoners" market, health care stocks languish.
Profiting from these companies' steady long-term gains requires patience.
Novo is 'not yet screamingly cheap, but it is certainly approaching great value.'
Shares of Novo Nordisk were lower Thursday after announcing layoffs across its global business.
The ability to exit pricey shares with the chance to buy them back cheaper occurs with regularity.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Shares of Novo Nordisk popped 5% last week after the U.S. Food and Drug Administration (FDA) approved the application for its long-acting insulin drug Tresiba.
Here are some of the best pharmaceuticals our algorithm says you should consider looking at.
Overall, slightly more than half the charts scored a 'B' or better.
As health-care stocks rally, it's time for politicians to move on.